Cargando…
Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine
Autores principales: | Yu, Zhaojin, Liu, Wensi, He, Ying, Sun, Mingli, Yu, Jiankun, Jiao, Xue, Han, Qiang, Tang, Haichao, Zhang, Bing, Xian, Yunkai, Qi, Jing, Gong, Jing, Xin, Wang, Shi, Gang, Shan, Fengping, Zhang, Rui, Li, Jianping, Wei, Minjie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482666/ https://www.ncbi.nlm.nih.gov/pubmed/34587994 http://dx.doi.org/10.1186/s13045-021-01176-1 |
Ejemplares similares
-
HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8(+) T and NK cells: a novel therapeutic tumour vaccine
por: Yu, Zhaojin, et al.
Publicado: (2021) -
The Analysis of Key Factors Related to ADCs Structural Design
por: Tang, Haichao, et al.
Publicado: (2019) -
Integrated microenvironment‐associated genomic profiles identify LRRC15 mediating recurrent glioblastoma‐associated macrophages infiltration
por: Tang, Haichao, et al.
Publicado: (2021) -
Peptide‐based therapeutic cancer vaccine: Current trends in clinical application
por: Liu, Wensi, et al.
Publicado: (2021) -
Designing high affinity target-binding peptides to HLA-E: a key membrane antigen of multiple myeloma
por: Yang, Ying, et al.
Publicado: (2020)